{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-24-000068","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.826682+00:00","generated_at":"2026-05-31T10:03:30.935441+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Caribou Biosciences appoints Tina Albertson, MD PhD, as Chief Medical Officer","bullets":["Dr. Albertson brings 15 years of experience in cellular therapy development, most recently as CMO at Lyell Immunopharma.","At Juno Therapeutics (BMS), she led global development of BREYANZI from IND to BLA filing and FDA approval.","She will oversee clinical, regulatory, and medical affairs for Caribou's four CAR-T cell therapy programs.","Dr. Albertson reports to CEO Rachel Haurwitz and will drive allogeneic CAR-T development in hematologic and autoimmune diseases."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-24-000068","json":"https://secwatch.observer/filing/0001619856-24-000068.json","markdown":"https://secwatch.observer/filing/0001619856-24-000068.md","text":"https://secwatch.observer/filing/0001619856-24-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985624000068/0001619856-24-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985624000068/crbu-20240812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:03:30.935441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}